Amylin takes heart from QT data but FDA awaits full QT study
This article was originally published in Scrip
Executive Summary
An analysis of a Phase III clinical trial (DURATION-1) by Amylin, Lilly and Alkermes shows that Bydureon was not associated with clinically relevant QT prolongation, an indication of heart arrhythmias, presenting reassuring information for investors. Bydureon is the once-weekly version of the glucogen-like peptide-1 agonist exenatide in type 2 diabetes, still under review by the US regulators.